J., Kyloh, M
In a study published in the Journal of Managed Care and Specialty Pharmacy, Sujith Ramachandran, associate professor of pharmacy administration, said that "cost-effective" does not necessarily mean "cost-saving" for insurance companies
I., Tentolouris, N., & Buse, J
MAN has participated in advisory boards or was invited as speaker by Amylin Pharmaceuticals, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Diartis Pharmaceuticals, Inc., Eli Lilly & Co., GlaxoSmithKline, Hoffmann-La Roche Ltd, Intarcia Therapeutics, Inc., Janssen Global Services, MannKind Corp., Merck Sharp & Dohme GmbH, Novo Nordisk, Novartis, Sanofi-Aventis, Takeda, Versartis, Wyeth Research
Gen Comp Endocrinol (2017) 252:1429.10.1016/j.ygcen.2017.08.008 134 YoungRLChiaBIsaacsNJMaJKhooJWuTet alDisordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes
(jofem.org) The best-case signal: modest weight loss in a shorter trial A frequently cited 12-week randomized trial result (as summarized in reviews) reported: ~2.6 kg average loss with AOD-9604 1 mg/day vs ~0.8 kg with placebo (PMC) This is the kind of result that can be statistically meaningful, clinically modest, and very sensitive to study design (diet, activity, baseline metabolic status, adherence)